Phosphate ion

Generic Name: Phosphate ion

Drug Type: Small Molecule

Chemical Formula: O_₄P

CAS Number: 14265-44-2

Unique Ingredient Identifier: NK08V8K8HR

Clinical Trials

Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy

Phase 4

Recruiting

Conditions: Tonsillectomy
Pain
PONV
Bleeding

Interventions: Drug: Betamethason Sodium Phosphate
Drug: 10% glucose solution

First Posted Date: 2018-12-20

Last Posted Date: 2024-05-14

Lead Sponsor: Umeå University

Target Recruit Count: 100

Registration Number: NCT03783182

Locations: 🇸🇪
Sunderby sjukhus, Luleå, Sweden

The Impact of Phosphate Metabolism on Healthy Aging

Early Phase 1

Suspended

Conditions: XLH
HHRH
Rickets
Hypercalciuria
Hypophosphatemia

Interventions: Drug: phosphate

First Posted Date: 2018-12-10

Last Posted Date: 2024-02-15

Lead Sponsor: Yale University

Target Recruit Count: 30

Registration Number: NCT03771105

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Not Applicable

Recruiting

Conditions: Hyperphosphatemia
Kidney Failure, Chronic

Interventions: Drug: Intensive phosphate target
Drug: Liberal phosphate target

First Posted Date: 2018-06-29

Last Posted Date: 2024-10-16

Lead Sponsor: The University of Queensland

Target Recruit Count: 3600

Registration Number: NCT03573089

Locations: 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺
Townsville University Hospital, Townsville, Queensland, Australia
🇦🇺
St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia

and more 96 locations

Effects of ACS in Twin With LPB: Study Protocol for a RCT

Phase 2

Completed

Conditions: Twin Pregnancy, Antepartum Condition or Complication

Interventions: Drug: Normal saline
Drug: Betamethason Sodium Phosphate

First Posted Date: 2018-06-06

Last Posted Date: 2024-08-01

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 848

Registration Number: NCT03547791

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

Phase 1

Completed

Conditions: H7N9 Influenza

Interventions: Biological: Phosphate Buffer Solution
Biological: 15μg H7N9 Vaccine
Biological: 7.5μg H7N9 Vaccine
Biological: 30μg H7N9 Vaccine
Biological: Aluminum Hydroxide Adjuvant

First Posted Date: 2017-12-12

Last Posted Date: 2024-10-15

Lead Sponsor: Shanghai Institute Of Biological Products

Target Recruit Count: 360

Registration Number: NCT03369808

Locations: 🇨🇳
Suiping Center for Disease Control and Prevention, Zhumadian, Henan, China

The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis

Phase 4

Conditions: Hyperphosphatemia

Interventions: Drug: Niacin
Drug: Phosphate Binder

First Posted Date: 2017-05-23

Last Posted Date: 2017-05-23

Lead Sponsor: Assiut University

Target Recruit Count: 150

Registration Number: NCT03163576

Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.

Phase 1

Completed

Conditions: Botulinum Toxins, Type A
Plantar Fascitis

Interventions: Drug: Ropivacaine
Drug: Betamethason Sodium Phosphate
Drug: Botulinum Toxins, Type A

First Posted Date: 2017-02-15

Last Posted Date: 2020-05-27

Lead Sponsor: Universidad Autonoma de Nuevo Leon

Target Recruit Count: 60

Registration Number: NCT03054610

Locations: 🇲🇽
Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico

Alveolar Cleft Grafting Using Two Different Alloplastic Grafts

Phase 2

Conditions: Alveolar Cleft Grafting

Interventions: Drug: β- tricalcium phosphate alone
Drug: Puerarin
Drug: β- tricalcium phosphate

First Posted Date: 2017-01-11

Last Posted Date: 2017-01-11

Lead Sponsor: Cairo University

Target Recruit Count: 20

Registration Number: NCT03016793

Locations: 🇪🇬
Mohamad hamed Maklad, Suez, Egypt

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

Phase 3

Completed

Conditions: X-Linked Hypophosphatemia

Interventions: Biological: burosumab
Drug: Oral Phosphate Supplement
Drug: active vitamin D

First Posted Date: 2016-09-27

Last Posted Date: 2024-08-29

Lead Sponsor: Kyowa Kirin, Inc.

Target Recruit Count: 61

Registration Number: NCT02915705

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 13 locations

Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy

Phase 4

Conditions: Transient Hypoparathyroidism

Interventions: Drug: phosphate and betamethasone acetate, 2 mL.
Drug: saline 0.9% NaCl

First Posted Date: 2016-01-12

Last Posted Date: 2016-04-05

Lead Sponsor: Hospital Italiano de Buenos Aires

Target Recruit Count: 110

Registration Number: NCT02652884

Locations: 🇦🇷
Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy